Cargando…

Atypical Chronic Lymphocytic Leukemia—The Current Status

SIMPLE SUMMARY: The degree of differentiation of leukemic cells seen in clinical practice is significant. The dissimilarities concern morphology, cytogenetics, and immunophenotype. This leads to a distinction between typical chronic lymphocytic leukemia and the atypical one, which is not taken into...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robak, Tadeusz, Krawczyńska, Anna, Cebula-Obrzut, Barbara, Urbaniak, Marta, Iskierka-Jażdżewska, Elżbieta, Robak, Paweł
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527541/ https://www.ncbi.nlm.nih.gov/pubmed/37760396 http://dx.doi.org/10.3390/cancers15184427

Ejemplares similares

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Klonowska-Szymczyk, Agnieszka, et al.
Publicado: (2014)

Application of New Drugs in Chronic Lymphocytic Leukemia
por: Robak, Tadeusz
Publicado: (2010)

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development
por: Rogalińska, Małgorzata, et al.
Publicado: (2017)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Circulating proangiogenic cytokines and angiogenesis inhibitor endostatin in untreated patients with chronic lymphocytic leukemia.
por: Gora-Tybor, Joanna, et al.
Publicado: (2003)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia
por: Karabon, Lidia, et al.
Publicado: (2016)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia—a real-world analysis of the Polish Adult Leukemia Study Group
por: Soboń, Anita, et al.
Publicado: (2023)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

The role of NF-κB and Smac/DIABLO proteins in the treatment response and survival of acute myeloid leukemia patients
por: Pluta, Agnieszka, et al.
Publicado: (2019)

Book review: Safety of Biologics Therapy
por: Robak, Tadeusz
Publicado: (2017)

Serum levels of IL-6 type cytokines and soluble IL-6 receptors in active B-cell chronic lymphocytic leukemia and in cladribine induced remission.
por: Robak, T, et al.
Publicado: (1999)

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors
por: Kubczak, Małgorzata, et al.
Publicado: (2019)

Secondary malignancies and survival of FCR‐treated patients with chronic lymphocytic leukemia in Central Europe
por: Kósa, Fruzsina, et al.
Publicado: (2022)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox
por: Robak, Tadeusz, et al.
Publicado: (2021)

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
por: Robak, Ewa, et al.
Publicado: (2006)

MGMT promoter methylation as a potential prognostic marker for acute leukemia
por: Sobieszkoda, Dominika, et al.
Publicado: (2017)

Impaired apoptosis of megakaryocytes and bone marrow mononuclear cells in essential thrombocythemia: correlation with JAK2V617F mutational status and cytoreductive therapy
por: Treliński, Jacek, et al.
Publicado: (2012)

Gene expression of INPP5F as an independent prognostic marker in fludarabine-based therapy of chronic lymphocytic leukemia
por: Palermo, G, et al.
Publicado: (2015)

Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy
por: Gdynia, Georg, et al.
Publicado: (2018)

Toll-like receptors and their role in carcinogenesis and anti-tumor treatment
por: Wolska, Anna, et al.
Publicado: (2008)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
por: Urbańska-Ryś, Halina, et al.
Publicado: (2003)

P1221: DIFFUSE LARGE B-CELL LYMPHOMA RICHTER SYNDROME IN CHRONIC LYMPHOCYTIC LEUKEMIA – A RETROSPECTIVE ANALYSIS OF TREATMENT OUTCOMES IN POLISH ADULT LEUKEMIA STUDY GROUP
por: Sośnia, O., et al.
Publicado: (2022)

The Expression of the SLIT–ROBO Family in Adult Patients with Acute Myeloid Leukemia
por: Gołos, Aleksandra, et al.
Publicado: (2019)

Imbalance of Th17 and T-regulatory cells in peripheral blood and synovial fluid in treatment naïve children with juvenile idiopathic arthritis
por: Szymańska-Kałuża, Joanna, et al.
Publicado: (2014)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c7gkfhi0u6264et4p2o9cog31f